Sort
46,585 grants matching “heart failure”
Clinical Utility of Endothelial Function in PAD
$999,902Boston Medical Center · R01 · FY2003 · HL
Implantable Unpinning Termination Therapy for Cardiac Arrhythmias
$999,810Jeffrey Peters · Cardialen, Inc. · R44 · FY2022 · HL
Development and Preclinical Testing of the TORVAD Ventricular Assist System in Preparation for First in Human Implantation
$999,796Jeffrey Robert Gohean · Windmill Cardiovascular Systems, Inc. · R44 · FY2017 · HL
Long Term Extracorporeal Oxygenating Device
$999,718Jean Montoya · Medarray, Inc. · R44 · FY2011 · HL
Molecular and Cellular Phenotype of Aging and iPS Cells
$999,701Joseph C Wu · Stanford University · RC1 · FY2010 · AG
Clinical Utility of Endothelial Function in PAD
$999,661Boston Medical Center · R01 · FY2004 · HL
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
$999,661Gerardo M. Castillo · Pharmain Corporation · R44 · FY2017 · HL
Long-acting PTH for hypoparathyroidism
$999,615Laura M Hales · Extend Biosciences, Inc. · R44 · FY2024 · DK
Long-acting PTH for hypoparathyroidism
$999,615Laura M Hales · Extend Biosciences, Inc. · R44 · FY2025 · DK
Development of Chemistry, Manufacturing, and Control Standards for PGC and PGC-dANP
$999,596Gerardo M. Castillo · Pharmain Corporation · R44 · FY2018 · HL
Clinical Utility of Endothelial Function in PAD
$999,588Boston Medical Center · R01 · FY2005 · HL
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass
$999,580Jonathan A Winger · Omniox, Inc. · R44 · FY2023 · HD
SBIR Phase II: Development of motion artifact correction systems for ViTrack: an accurate, continuous, and non-invasive blood pressure monitor
$999,553Mohan Thanikachalam · Dynocardia, Inc. · · FY2024 · TIP
BiVACOR - A Physiological, Durable and Blood-Friendly Total Artificial Heart
$999,517Daniel Timms · Bivacor, Inc. · R44 · FY2021 · HL
Iridium-electrode inhaled Nitric Oxide generator for treatment of hypoxic respiratory failure in neonates
$999,466Philip E Silkoff · Third Pole, Inc. · R44 · FY2019 · HL
Look AHEAD: Action for Health in Diabetes
$999,397John M Jakicic · University Of Pittsburgh At Pittsburgh · U01 · FY2010 · DK
Study of Osteoporotic Fractures
$999,380Steven R Cummings · California Pacific Med Ctr Res Institute · R01 · FY2012 · AG
Development and Preclinical Testing of the TORVAD Ventricular Assist System in Preparation for First in Human Implantation
$999,377Jeffrey Robert Gohean · Windmill Cardiovascular Systems, Inc. · R44 · FY2016 · HL
Implantable Unpinning Termination Therapy for Cardiac Arrhythmias
$999,374David W Bourn · Cardialen, Inc. · R44 · FY2021 · HL
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection
$999,300Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2022 · AI
Development and Preclinical Testing of the TORVAD Ventricular Assist System in Preparation for First in Human Implantation
$999,107Jeffrey Robert Gohean · Windmill Cardiovascular Systems, Inc. · R44 · FY2019 · HL
Stream Dx: Point of Care Cellular Enabled IoT Communication Hub for Improved Diagnosis, Monitoring, and Post-Treatment Evaluation of LUTS
$998,995Scott Bradford McClellan · Stream Dx, Inc. · R44 · FY2019 · DK
Implantable Unpinning Termination Therapy for Cardiac Arrhythmias
$998,941Jeffrey Peters · Qrs Diagnostic · R44 · FY2023 · HL
Development of highly potent human monoclonal for RSV immuno-prophylaxis
$998,825Larry Zeitlin · Mapp Biopharmaceutical, Inc. · R44 · FY2020 · AI
Safety of Allogeneic Cardiosphere-Derived Cells for Dilated Cardiomyopathy
$998,765Rachel Ruckdeschel Smith · Capricor, Inc. · R44 · FY2014 · HL